Cardiol Therapeutics Inc Class A (CRDL)

Wall Street Zen has upgraded Cardiol Therapeutics (NASDAQ:CRDL) from a "Sell" to a "Hold" rating, aligning with the overall average "Hold" rating from analysts and an $8.50 price target. CRDL shares rose 5.3% to $1.80, with a market cap of $208.6 million, and the company reported a quarterly EPS of -$0.04, outperforming consensus estimates. Institutional investors collectively own 12.49% of the company, which focuses on developing immunomodulatory treatments for cardiovascular disease.

MMCAP International Inc. SPC and MM Asset Management Inc. have reported a beneficial ownership of 21,310,099 Class A Common Shares in Cardiol Therapeutics Inc. (CRDL) as of June 30, 2026. This stake represents 17.6% of the company's Class A Common Shares, including both directly held shares and shares underlying warrants exercisable within 60 days. Both entities share voting and dispositive power over these shares.

Cardiol Therapeutics (NASDAQ:CRDL) recently announced its quarterly earnings, reporting an EPS of ($0.04), which surpassed analyst expectations of ($0.09) by $0.05. Following the announcement, the company's shares increased by 1.3% to $1.52, with a market capitalization of approximately $176.15 million. Analyst sentiment for CRDL is mixed, with a consensus "Hold" rating and an $8.50 price target from two Buy and one Sell rating.

Cardiol Therapeutics (TSX:CRDL) is a clinical-stage life sciences company focused on developing therapies for cardiovascular conditions, with its research strategy centered on addressing unmet therapeutic needs in this area. The company's future hinges on clinical execution, regulatory developments, and the quality of its trial evidence. Key factors influencing its outlook include clinical trial updates, regulatory interactions, and scientific presentations at industry conferences, all of which will determine the progression of its pipeline towards advanced development and potential commercialization.

Cardiol Therapeutics is nearing a crucial Phase III readout for its lead drug, CardiolRx, in recurrent pericarditis. The company presented its clinical and commercial strategy at Canaccord Genuity's 46th Annual Growth Conference, highlighting the drug's potential, market opportunity, and positive payer feedback. Despite the promising outlook, management emphasized that the coming months are critical for trial execution and regulatory outcomes.